Cargando…

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis

INTRODUCTION: The aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged ≥ 50 years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Daisuke, Mizukami, Akiko, Holl, Katsiaryna, Curran, Desmond, Van Oorschot, Desirée, Varghese, Lijoy, Shiragami, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002317/ https://www.ncbi.nlm.nih.gov/pubmed/29680914 http://dx.doi.org/10.1007/s13555-018-0236-3

Ejemplares similares

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
por: McGirr, Ashleigh, et al.
Publicado: (2019)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study
por: Mizukami, Akiko, et al.
Publicado: (2017)

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan
por: Nakamura, Hiroyuki, et al.
Publicado: (2017)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014
por: Imafuku, Shinichi, et al.
Publicado: (2018)

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy
por: Volpi, Antonio, et al.
Publicado: (2019)

A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life
por: Van Oorschot, Desirée, et al.
Publicado: (2022)

Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above
por: Curran, Desmond, et al.
Publicado: (2018)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
por: Matthews, Sean, et al.
Publicado: (2019)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting
por: Sauboin, Christophe, et al.
Publicado: (2019)

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study
por: Díez-Domingo, Javier, et al.
Publicado: (2021)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Lifetime risk of herpes zoster in the population of Beijing, China
por: Lee, Christa, et al.
Publicado: (2023)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France
por: Blein, Cecile, et al.
Publicado: (2015)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Risk of Herpes Zoster in Relation to Body Mass Index Among Residents Aged ≥50 Years: The Shozu Herpes Zoster Study
por: Kawahira, Kazuhiro, et al.
Publicado: (2022)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Herpes Zoster
por: Warneros Loyo, María de Lourdes
Publicado: (1995)

Herpes Zoster
Publicado: (1890)

Herpes Zoster
por: Wile, Henry
Publicado: (1886)

Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials
por: Curran, Desmond, et al.
Publicado: (2022)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China
por: Zhu, Qi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_no1rosgh3rlqd65srlp48hj392